Literature DB >> 6803361

Second malignancies associated with chemotherapeutic agents.

R A Kyle.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6803361

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  9 in total

1.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

2.  Hemangiopericytoma of the heart following treatment of Hodgkin's disease. A case report.

Authors:  K W Schmid; J Thurner; K Gruenewald
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

3.  Chronic myelocytic leukemia as a secondary malignant condition in a patient receiving prolonged chemotherapy for ovarian carcinoma.

Authors:  M Markman
Journal:  West J Med       Date:  1985-08

Review 4.  Implications of tumor progression on clinical oncology.

Authors:  D R Welch; S P Tomasovic
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

5.  Increasing rates of DNA single-strand breaks in lymphocytes of clinical personnel handling cytostatic drugs.

Authors:  M Reitz; S Afghanyar; P Gutjahr
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Osteosarcoma after chemotherapy for neuroblastoma.

Authors:  V M Kriss; C B Stelling
Journal:  Skeletal Radiol       Date:  1995-11       Impact factor: 2.199

7.  Primary brain lymphomas in patients with a prior or concomitant malignancy.

Authors:  M Reni; A J Ferreri; M C Zoldan; E Villa
Journal:  J Neurooncol       Date:  1997-04       Impact factor: 4.130

8.  Measurements of the frequency of human erythrocytes with gene expression loss phenotypes at the glycophorin A locus.

Authors:  R G Langlois; W L Bigbee; R H Jensen
Journal:  Hum Genet       Date:  1986-12       Impact factor: 4.132

Review 9.  The process of leukemogenesis.

Authors:  R D Irons; W S Stillman
Journal:  Environ Health Perspect       Date:  1996-12       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.